MACDONALD JOHN R 4

4 · MGI PHARMA INC · Filed Feb 15, 2005

Form 4

Period: 2005-02-14

Sr. VP, Research & Development

Transactions

Sale
Common Stock
2005-02-15$25.03/sh−20,250$506,868→ 11,676 total
Exercise/Conversion
Employee Stock Option-Right to Buy
2005-02-15−20,000→ 0 total
Exercise: $1.97From: 2002-01-14Exp: 2008-01-14→ Common Stock (20,000 underlying)
Exercise/Conversion
Common Stock
2005-02-15$2.29/sh+250$572→ 11,926 total
Exercise/Conversion
Common Stock
2005-02-15$1.97/sh+20,000$39,376→ 31,926 total
Exercise/Conversion
Common Stock
2005-02-14$2.41/sh+7,750$18,649→ 19,426 total
Exercise/Conversion
Common Stock
2005-02-14$2.29/sh+2,250$5,150→ 21,676 total
Sale
Common Stock
2005-02-14$25.00/sh−10,000$250,000→ 11,676 total
Exercise/Conversion
Employee Stock Option-Right to Buy
2005-02-14−2,250→ 250 total
Exercise: $2.29From: 2001-11-11Exp: 2007-11-11→ Common Stock (2,250 underlying)
Exercise/Conversion
Employee Stock Option-Right to Buy
2005-02-15−250→ 0 total
Exercise: $2.29From: 2001-11-11Exp: 2007-11-11→ Common Stock (250 underlying)
Exercise/Conversion
Employee Stock Option-Right to Buy
2005-02-14−7,750→ 0 total
Exercise: $2.41From: 2001-01-14Exp: 2007-01-14→ Common Stock (7,750 underlying)

Holdings

Footnotes (2)

[F1]These shares sold pursuant to a 10(b)5-1 plan filed on November 9, 2004.
[F2]Filing dated July 16, 2004 incorrectly reported a tandem Limited Stock Appreciation Right which is not attached to this option grant.

Documents

1 file